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Cardiovascular disease (CVD) still remains the main cause of morbidity and mortality and consequently early diagnosis is of
paramount importance. Working conditions can be regarded as an additional risk factor for CVD. Since different aspects of the job
may affect vascular health differently, it is important to consider occupation frommultiple perspectives to better assess occupational
impacts on health. Standard echocardiography has several targets in the cardiac population, as the assessment of myocardial
performance, valvular and/or congenital heart disease, and hemodynamics.Three-dimensional echocardiography gained attention
recently as a viable clinical tool in assessing left ventricular (LV) and right ventricular (RV) function, volume, and shape. Two-
dimensional (2DSTE) and, more recently, three-dimensional speckle tracking echocardiography (3DSTE) have also emerged as
methods for detection of global and regionalmyocardial dysfunction in various cardiovascular diseases and applied to the diagnosis
of subtle LV and RV dysfunction. Although these novel echocardiographic imaging modalities have advanced our understanding
of LV and RV mechanics, overlapping patterns often show challenges that limit their clinical utility. This review will describe the
current state of standard and advanced echocardiography in early detection (secondary prevention) of CVD and address future
directions for this potentially important diagnostic strategy.
1. Introduction
Cardiovascular disease (CVD) still remains the main cause
of morbidity and mortality [1, 2] and consequently early
diagnosis is of paramount importance. Although the divi-
sion of prevention of cardiovascular disease into primary,
secondary, and tertiary prevention is arbitrary, it may be
useful for development of services by different parts of the
health care system. Working conditions can be regarded
as an additional risk factor for CVD [3]. Since different
aspects of the job may affect vascular health differently, it
is important to consider occupation from multiple perspec-
tives to better assess occupational impacts on health [4].
Standard echocardiography has several targets in the cardiac
population, as the assessment of myocardial performance,
valvular and/or congenital heart disease, and hemodynam-
ics. Three-dimensional echocardiography gained attention
recently as a viable clinical tool in assessing left ventricu-
lar (LV) and right ventricular (RV) function, volume, and
shape. Two-dimensional (2DSTE) and, more recently, three-
dimensional speckle tracking echocardiography (3DSTE)
have also emerged as methods for detection of global and
regional myocardial dysfunction in various cardiovascular
diseases [5–9] and applied to the diagnosis of subtle LV and
RV dysfunction. Although these novel echocardiographic
imaging modalities have advanced our understanding of
LV and RV mechanics, overlapping patterns often show
challenges that limit their clinical utility. This review will
describe the current state of standard and advanced echocar-
diography in early detection (secondary prevention) of CVD
and address future directions for this potentially important
diagnostic strategy.
2. Cardiovascular Disease in Workers
Atherosclerosis, the basis of coronary artery disease (CAD),
develops into a complex process [10]. CAD is recognized as
a paraoccupational disease; thus working conditions could
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be regarded as a possible risk factor for disease onset,
development, or deterioration [11].The relationships between
psychosocial work load and CAD, as well as interactions
among neuropsychological and immunological systems, have
also attracted attention [12].
Although stress-related disorders comprise only a small
fraction of occupational injuries and illnesses [11], overall the
median time away from work is more than four times greater
for stress-related conditions than for all other diseases.Work-
related stress (WRS) is thought to contribute to several
occupational illnesses including cardiovascular disease. All
the cohort studies and most cross-sectional studies found
greater carotid artery intima-media thickness (CIMT) with
higher levels ofWRS.A large body of literature showed a close
relationship betweenWRS and CAD [13–24] as well as a rela-
tionship between occupational stress and early atheroscle-
rotic changes found in carotid ultrasound examinations [25–
29]. Differences in body mass index, systemic hypertension,
and smoking across studies may explain some conflicting
results [11] since selection of patients may be a challenge
in interpreting occupational epidemiology data. Actually,
workers in high strain jobs may have bad health behaviors
that cannot be adequately adjusted for statistical models and
act as confounding factors. Additionally, workers with known
heart disease could choose jobs with lesser degrees of stress
or leave overall their work, and people who work in high
strain occupations who develop heart diseasemay potentially
change their positions with new ones with lower degrees of
stress. However, the triad of occupational exposures, such
as shift work, noise, and physical workload [3], emerged as
significant risk factor of CAD.Their joint effects did not show
any high risk peaks, but the relative risk of those with all three
risk factors present was about twofold compared with those
with none of the factors. In another study [20], in comparison
with daytime-only workers, rotating shift workers reported
higher job strain, exhibited flatter 𝛼-amylase and cortisol
diurnal slopes, reduced daily 𝛼-amylase production, elevated
daily cortisol production, and reduced heart rate variability
and endothelial functioning.
A deleterious effect of shift work was also shown on
lipidmetabolism [21–24].Womenworking in a rapid forward
rotating shift pattern had poorer sleep quality according
to self-reported indicators of the validated Pittsburgh Sleep
Quality Index and they had a higher prevalence of the
metabolic syndrome compared with women working during
the day only [21].Working shiftwas, independently of lifestyle
or BMI, significantly related to more elevated plasma triglyc-
erides and rate of hypertriglyceridemia, lower plasma HDL-
C levels, and hypertension compared to nonshift daytime
work [22]. The prevalence of lifestyle-related risk factors
including hypertension, diabetes, dyslipidemia, metabolic
syndrome, and obesity was higher in men than women and
higher overall in workers aged 60–69 years [23], reinforcing
the importance of developing effective strategies for the
prevention of cardiovascular disease amongmiddle-aged and
older workers, especially in men.
Many features of the environment exert an important
influence on CVD risk, progression, and severity. Numerous
epidemiological and experimental studies showed that air
pollution [25, 26] causes a systemic vascular oxidative stress
reaction. Increased cardiovascular mortality was also related
to long-term and short-term exposure to nitrogen dioxide.
Exposure to air pollution and road traffic was associated with
an increased risk of arteriosclerosis with premature aortic and
coronary calcification and increased risk of systemic hyper-
tension,myocardial infarction, stroke, and acute heart failure.
The Global Burden of Disease Study 2015 ranked ambient
exposure to fine particulate matter with an aerodynamic
diameter of <2.5 𝜇m (PM
2.5
) as the fifth most important
risk factor for mortality worldwide and the burden from
air pollution was comparable to that from hypertension
and diabetes mellitus [25]; thus it should be considered
an important modifiable environmental cardiovascular risk
factor.
Whereas the link between occupation and cardiovascular
disease has been recognized, it is unclear which role occupa-
tion plays in the progression of subclinical CVD measured
as carotid intima-media thickness (CIMT). Few longitudinal
studies exist about occupation and subclinical CVD. Further-
more often these studies do not examine whether occupation
is only an indicator of the person’s socioeconomic position
or a source of potentially health-compromising exposures.
While in the former approach occupational differences show
the socioeconomic gradient in CVD, in the latter approach
occupation represents additional damage to the risk profile.
A weak positive correlation was found between CIMT
and age, diastolic blood pressure, LDL cholesterol, and
antiphospholipid antibodies, and a negative correlation with
the presence of anti-cardiolipin antibodies and a general
level of occupational stress [26–28]. A more complicated
association was shown between occupational mobility and
CIMT [29]. Specifically, for those patients with lower initial
occupational standings, upwardmobility was associated with
less CIMT and downward mobility with greater CIMT,
whereas for those with higher initial standings, upward
mobility was associated with greater CIMT while downward
mobility was unrelated to either CIMT measure.
3. Role of Echocardiography in
Early Diagnosis of Specific CVD
3.1. Coronary Heart Disease. Coronary artery disease or
ischemic heart disease (CAD or IHD) is one of the major
causes of morbidity and mortality. Echocardiography pro-
vides a thorough complex assessment of structural and hemo-
dynamic changes induced by acute or chronic CAD [30–32],
and in skilled hands it is useful for the clinicalmanagement of
these patients. Despite its undeniable operator dependence,
its availability, ease of use, price, capacity to serve as bedside
technique, and repeatabilitymake themethod essential for all
cardiologists.
Myocardial ischemia impairs regional systolic contractil-
ity. Persistence of severe ischemia produces development of
myocardial necrosis and scarring with permanent functional
impairment (Figure 1). Regional myocardial function is usu-
ally assessed only visually by assessing wall thickening and
endocardial motion of myocardial segments, and is graded
depending on the quality of contraction. The recommended
BioMed Research International 3
(a) (b)
(c) (d)
Figure 1: A 43-year-old male patient with anteroapical myocardial infarction. Subsequent stent implantation in the left anterior descending
(LAD) coronary artery and medical therapy. (a) Dilated left ventricle (LV) in long axis view. (b) Akinetic scarred septum (IVS) in M-mode
representation. (c) Dilated LV in apical 4-chamber view with mitral valve (MV) regurgitation. (d) White scarred segments compared to
red normokinetic segments in the “bull’s-eye” plot by speckle-tracking echocardiography. Strain curves show reduction of anteroapical
longitudinal strain. Ao = aorta; LA = left atrium; PW = LV posterior wall.
scoring [32] is as follows: (1) normal or hyperkinetic, (2)
hypokinetic (reduced thickening), (3) akinetic (absent or
negligible thickening), and (4) dyskinetic (systolic thinning
or stretching or aneurysm). Based on the segmental motion
evaluation a wall motion score index (WMSI) can be calcu-
lated as a sumof all scores divided by the number of visualized
segments. The segmentation of the left ventricular cavity is
usually based on a 17-segments model.
The use of deformation (“strain”) echocardiography
allows less subjective assessment of myocardial contrac-
tion as compared to simple visual evaluation [33–36]. The
strain and strain rate derived from two-dimensional speckle
tracking echocardiography (2DSTE) are based on computer
algorithms tracking the movement of the so-called “speck-
les,” clusters of natural acoustic markers generated within
the myocardium by an interaction with ultrasonic waves
(Figure 1). Compared to Doppler techniques, this modality is
independent of the ultrasound beam propagation angle and
allows evaluation of longitudinal, radial, and circumferential
strains.
Since in the normal myocardium strains and strain rates
are homogenously distributed, subtle strain changes sug-
gest myocardial contractile impairment. A good correlation
has been shown between longitudinal strain decrease and
reduced coronary perfusion in segments that appear visually
normal. In addition to regionalmyocardial strain assessment,
a global longitudinal strain (GLS) can be determined averag-
ing peak longitudinal strain in all evaluable segments. GLS
is compromised in CAD patients and appears as a useful
index for assessment of global myocardial function. A GLS
cut-point of greater than −17.77% had good sensitivity and
specificity for detecting CAD andwas comparable to aWMSI
≥ 1.13 measured during stress [34]. Unfortunately there is
a disparity in results depending on the software and the
vendor used.Thus the current recommendations on chamber
quantification suggest normal values of GLS for a healthy
individual around 20%but studies are in progress and routine
clinical application of myocardial strain is not yet reached.
Three-dimensional speckle tracking echocardiography
(3DSTE) has recently been regarded as a more promis-
ing technique to accurately and reproducibly evaluate the
segmental and global LV function [36]. The 3D mode
avoids foreshortening of apical views, consumes less time
in data acquisition, helps to solve the problem of out-of-
plane motion present in the 2D modality tracking motion
of speckles in all three dimensions, needs one single apical
4-chamber view to carry out all the analysis, and has good
reproducibility as automated method as shown by the lower
intraobserver and interobserver variability. However, this
advantage is achieved at the expense of lower frame/volume
rate, lower temporal resolution, and higher dependence on
image quality with possible inappropriate tracking due to
dropouts in the endocardial border in patients with poor
acoustic windows.
The role of 2D stress echocardiography (SE), either exer-
cise (exercise SE) or pharmacologic with dobutamine (DSE),
is well established for diagnosis and prognosis of patients
with known or suspected CAD [7, 37–52]. Appropriate uses
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Figure 2: Provocative testing in ischemic heart disease. (a) Exercise stress echocardiography in a patient with normal coronary arteries.
Persistent normal wall motion after exercise (125W). (b) Dobutamine stress echocardiography in a patient with ischemic heart disease.
Anteroseptal hypokinesia at peak dose (40mcg) is shown both by wall motion abnormalities (top panels) and strain analysis (bottom right
panel, lighter segments in the “bull’s-eye” representation of peak systolic strain). LV = left ventricle.
of exercise SE (Figure 2) are low pretest probability of CAD
and ECG uninterpretable or unable to exercise and high
or intermediate pretest probability of CAD regardless of
ECG interpretability and ability to exercise. An imaging
stress test is also recommended in symptomatic patients with
prior revascularization, to assess the functional severity of
intermediate lesions on coronary arteriography, and as the
initial test for diagnosing CAD if the left ventricular ejection
fraction is <50% in patients without typical angina [40–42].
The dobutamine stress test (DSE) should be carried out when
an exercise test cannot be performed.
The sensitivity of SE is higher for multivessel CAD and
lower for single vessel disease. Sensitivity of the test is also
influenced by the time between peak stress and image acqui-
sition. It is imperative to accomplish postexercise imaging as
soon as possible (≤1min from cessation of exercise). When
abnormalities recover rapidly, false-negative results occur.
On the other hand, despite the excellent specificity of SE,
some patients have false-positive tests (i.e., <50% diameter
coronary artery stenosis on the subsequent angiogram) in the
absence of left bundle branch morphology, right ventricular
pacing, prior cardiac surgery, or abnormal wall tethering at
baseline. These false-positive findings present a management
challenge because it remains unclear whether these patients
should be treated and how to treat them. A subset of
patients hasmicrovascular abnormalities [43], a hypertensive
response to exercise, vasomotor changes, endothelial dys-
function, and/or small vessel coronary disease that can lead
to false-positive SE.
2D-SE has its own limitations as multiple views of the
left ventricle (LV) must be obtained from more than win-
dow to completely visualize all segments. Three-dimensional
stress echocardiography (3D-SE) allows assessing overall wall
motion of the entire LV simultaneously in different planes
[44]. 3D images can be displayed in multiplane or multislice
views for ease of comparison with greater accuracy and
interobserver agreement when compared to 2D. 3D-SE is
quantitative, provides rapid image acquisition, avoids LV
foreshortening by correct alignment of imaging planes, and
is easily applied during pharmacologic stress and feasible
during exercise-induced stress. Despite these advantages,
3D has lower temporal and spatial resolution than 2D and
requires longer analysis time.
A major limitation of echocardiographic study interpre-
tation is the subjective visual analysis of endocardial motion
and wall thickening which is only semiquantitative.The need
for more quantitative techniques to objectively evaluate LV
regional wall motion duringDSE has led to the incorporation
of new indices in the analysis of regional wall motion.
Tissue Doppler imaging (TDI) is a novel echocardiographic
technique that can be used to quantitatively assess low-
velocity motion of myocardial walls with excellent temporal
resolution [45]. 2D-strain echocardiography (2DSTE) is a
highly sensitive alternative method of quantifying regional
myocardial performance on the basis of grayscale ultrasound
imaging. Several experimental studies have already vali-
dated 2D strain techniques against sonomicrometry during
dobutamine infusion and/or ischemia. Clinical studies have
investigated the diagnostic value of 2D strain and related
parameters during DSE for inducible ischemia detection in
patients with suspected CAD [7, 46, 47]. Two-dimensional
STE is feasible on full-protocol DSE after ST-segment ele-
vation myocardial infarction, provides incremental value to
conventional visual wall analysis, and represents a promising
new quantitative technique to detect significant angiographic
CAD at follow-up (Figure 2).
Regional LV akinesia inCADpatients is irreversible in the
presence of scarred tissue but may be reversible in stunned or
hibernated myocardium [48–52]. Stunning and hibernation
are different in terms of pathophysiology and clinical course
but have similar prognostic implications related to the degree
of LV dysfunction. Identification of viable myocardium
becomes of critical importance in patients with LV ejection
fraction <40% and high risk of mortality who may benefit
from any improvement of myocardial contractility.
Assessment of contractile response to inotropic stimu-
lation by low-dose dobutamine echocardiography or eval-
uation of myocyte metabolism with nuclear scan and
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Figure 3: A 48-year-old male patient with systemic arterial hypertension, left ventricular hypertrophy, and diastolic dysfunction. Patient was
onmedical therapy. (a) Concentric left ventricular hypertrophy. (b) Mitral inflow velocity with inverted 𝐸/𝐴 ratio. (c) Mitral annulus velocity
with inverted 𝐸
𝑎
/𝐴
𝑎
ratio. 𝐸
𝑎
reduction with increased 𝐸/𝐸
𝑎
ratio suggests diastolic dysfunction. 𝐴 = inflow late diastolic (atrial) velocity; 𝐸
= inflow early diastolic velocity; 𝐸
𝑎
= annular early diastolic velocity; IVS = interventricular septum; LV = left ventricle; PW = LV posterior
wall; RV = right ventricle; 𝑆
𝑎
= annular systolic velocity.
positron emission tomography is used to identify hibernating
myocardium. Recent clinical reports such as STICH trial
suggest that we should not rely on one single imaging
parameter and that optimal medical therapy may be some-
times as effective as revascularization procedures [49, 50].
However, although on the basis of the STICH trial there is
no evidence that assessment of myocardial viability should
not be included in the workup of patients with chronic LV
dysfunction, the role of cardiac imaging in clinical decision-
making could benefit from further studies.
3.2. Hypertensive Heart Disease. Hypertensive heart disease
represents a form of organ damage with strong independent
prognostic significance. Assessment of myocardial anatomy
and function is necessary to identify early cardiac alterations
in hypertensive patients since left ventricular hypertrophy
(LVH) is the first step toward the development of coronary
heart disease, stroke, heart failure, and sudden death. Recent
Guidelines of the American College of Cardiology/American
Heart Association [53] define normal blood pressure as
<120/80mmHg, elevated blood pressure 120–129/80mmHg,
hypertension stage 1 >130/80mmHg, and hypertension stage
2 ≥140/90mmHg and include echocardiography among the
recommended techniques to assess the presence of preclinical
organ damage in hypertensive patients (Figure 3). Although
the relationship between baseline LV mass and incidence of
cardiovascular events is independent of other cardiovascular
risk factors, LV mass reproducibility is a major technical
limitation of echocardiography since its calculation assuming
a prolate ellipsoid shape may be not reliable in patients with
asymmetrical hypertrophy or previous myocardial infarc-
tion. Observational studies as the LIFE [54] examined the
potential clinical benefits of regression of echocardiographic
detectable LVH during treatment, with important prognos-
tic significance. The LIFE study confirmed the prognostic
influence of LV geometry in addition to changes in LV
mass and the association of a concentric geometry during
treatment to a greater incidence of cardiovascular events.
Three-dimensional echocardiography provided better corre-
lations than 2D echowith cardiacmagnetic resonance (CMR)
measurements [55].
Echocardiography may also give useful information on
cardiac functional performance, including systolic and dias-
tolic changes (Figure 3). LV diastole may be examined by
assessment of transmitral flow velocities, mitral annular
pulsed tissue Doppler imaging, and left atrial volume [56].
Three-dimensional echocardiography improves the accuracy
of the evaluation of left ventricular and left atrial volumes
by eliminating the need for geometric modelling. Global
LV longitudinal strain is a clinically useful parameter to
identify subclinical systolic myocardial dysfunction [57].
In addition, LV segmental and global diastolic strain rate
and diastolic untwist may be used to assess relaxation
and diastolic function. Thus, 3D echocardiography, speckle
tracking echocardiography, andCMR are themost promising
methods to provide accurate assessment of cardiac structure
and function for early detection of preclinical organ damage.
Systemic hypertension may be a potential independent
risk factor for heart failure with preserved ejection fraction,
and LV diastolic filling changes can be observed even in
the absence of LV remodeling. Since the left atrium (LA) is
directly exposed to LV pressures during ventricular diastole,
LA size is correlated with LV filling pressure. Thus, LA
structural remodeling represents a stable indicator of the
severity of LV diastolic dysfunction [58–61]. Besides LA
structure, assessment of LA function is a further step toward
early diagnosis of abnormal LA-LV coupling (Figure 4). The
development of two-dimensional speckle-tracking echocar-
diography (2DSTE) has facilitated the early detection of
LA and LV dysfunction in the absence of LA dilatation or
impaired LV relaxation and in the presence of preserved LV
ejection fraction [62]. LV diastolic and systolic dysfunction
was shown to be a potent independent predictor of LA
structural and functional changes in asymptomatic patients
with hypertension. The use of 2DSTE gave new insights
into alterations in LA structure and function related to LV
dysfunction, underlining the key role of LA-LV coupling.
The role of arterial stiffness in systemic hypertension has
also been demonstrated and is based on its pathophysio-
logical importance for overall cardiovascular performance
[63–68]. The European guidelines for arterial hypertension
suggested aortic pulsewave velocity as a tool for assessment of
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Figure 4: Left atrial (LA) size and function in systemic arterial hypertension. Novel technologies for LA analysis. (a) LA wall deformation
curve by speckle tracking echocardiography. (b) LA volume by three-dimensional echocardiography. ACS = atrial contraction strain; PS =
peak strain (peak global longitudinal strain at ventricular end-systole).
subclinical target organ damage [63]. Large artery stiffening
increases LV afterload and is associated with LVH and
impaired coronary perfusion [66]. Moreover, stiffening of
large arteries is involved in the pathogenesis of hypertension
[67, 68]. Aortic stiffness was shown to have a predictive
value independent of classic cardiovascular risk factors and
other potential confounders and to integrate the effect of
the genetic background and the cumulative damage of risk
factors on the arterial wall.The risk associated with increased
arterial stiffness is similar to the risk of established risk
predictors commonly used in clinical practice, such as LVH.
Furthermore, it is a powerful predictor of all-cause mortality
in addition to cardiovascular outcomes.
3.3. Heart Failure. Heart failure (HF) is a common clinical
syndrome, especially in the elderly, but its diagnosis is often
missed. A detailed clinical history is crucial and should
address not only current signs and symptoms of heart failure
but also those signs pointing to a specific cause of the
syndrome, such as coronary artery disease, hypertensive
heart disease, or valvular heart disease. Echocardiographic
imaging has several targets in the HF population, including
the assessment ofmyocardial structure and function, valvular
disease, and hemodynamics.
All modalities of echocardiography are useful in the
assessment of the HF patient [69–73]. Historically, M-mode
echocardiography was the first technique, and it remains
helpful for accurate assessment ofwall thickness and chamber
dimensions. The use of two-dimensional (2D) echocardio-
graphy has enhanced the assessment of LV volumes and
valvular disease. Three-dimensional (3D) echocardiography
has further improved the accuracy of measurements of
chamber volumes and function and structural evaluation of
regurgitation. Doppler assessment of hemodynamics in HF
includes evaluation of pulmonary artery pressure, right atrial
pressure, LV filling, and valvar regurgitation. Analysis of
longitudinal and radial strain provides clinical applications
in the assessment of subclinical ventricular dysfunction and
dyssynchrony.
Two-dimensional echocardiographic assessment of LV
ejection fraction is based on measuring end-diastolic and
end-systolic volumes [32, 69–71] using different geometric
models (length-diameter and length-area methods, Simp-
son’s rule method, and modified Simpson’s rule). These
methods have shown good correlation with angiographic
data for the assessment of left ventricular ejection frac-
tion (LVEF), with normal LVEF generally considered to be
≥55–60%. Values below 50% are considered abnormal, and
patients with LVEF ≤ 40% are considered to have signif-
icant systolic dysfunction (Figure 5) requiring initiation of
specific medical therapy such as ACE-inhibitors, ß-blockers,
and diuretics. Limitations of 2D-TTE include its operator-
dependability and the inherent geometric assumptions of
LV cavity.Three-dimensional echocardiography has emerged
recently as a valid technique in assessing LV function,
volume, and shape (Figure 5). Its ability to spatially define the
cardiac structures in three-dimensional planes obviates the
geometric assumptions necessary for 2D echocardiography.
With further improvement, it has the potential to become an
important complement for ejection fraction assessment.
Most HF patients have reduced LV systolic function;
however a significant subset has normal or near normal
resting systolic function with predominantly diastolic dys-
function [56, 74–77]. The distinction between systolic (LVEF
< 35–40%) and diastolic (normal or elevated LVEF) dys-
function is critical for selecting proper therapies, since both
entities may manifest clinically with indistinguishable signs
and symptoms, but treatment and prognosis may be very
different.
Diastolic dysfunction causes impairment of LV relaxation
and compliance and consequent elevation of LV filling
pressures, left atrial pressures, pulmonary venous pressures,
pulmonary capillary pressures, and right heart pressures.
Cardiac performance is compromised with exercise, even in
the presence of normal stroke volume and cardiac output
at rest. Doppler echocardiography can help in the diagnosis
by allowing assessment of indices of diastolic filling and
ventricular relaxation. Myocardial hypertrophy (Figure 3)
and/or ischemia and myocardial fibrosis are the usual under-
lying pathologic processes for diastolic dysfunction and
decreased ventricular compliance, as well as the normal aging
process. Echocardiography can be used in cases of suspected
restrictive pathology to differentiate constrictive pericarditis
from infiltrative diseases such as myocardial amyloidosis
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Figure 5:A 48-year-oldmale patientwith dilated cardiomyopathy frompreviousmyocarditis and systolic dysfunction. Patientwas onmedical
therapy. (a) LV dilatation and septal (IVS) and posterior wall (PW) hypokinesia by M-mode echocardiography. (b) Two-dimensional four-
chamber apical view showing LV end-systolic dilatation and mitral valve (MV) regurgitation. (c) Three-dimensional four-chamber apical
view showing LV dilatation and severe systolic dysfunction (left ventricular ejection fraction = 32%). (d) Calculation of three-dimensional
right ventricular volumes showing right ventricular ejection fraction at lower normal limits (45%). GLS = global longitudinal strain; IVS =
interventricular septum; LV = left ventricle; LVEF = left ventricular ejection fraction; PW = LV posterior wall; RA = right atrium; RV = right
ventricle; RVEF = right ventricular ejection fraction.
and hemochromatosis. Tissue Doppler Imaging and Speckle
Tracking Echocardiography may also be helpful [73].
Thepresence of RVdysfunction has important prognostic
implications in patients with HF. RV dysfunction has often
been evaluated qualitatively, but the development of RV
annular systolic tissue velocity, RV free wall strain, and three-
dimensional RV volumes (Figure 5) has been an improve-
ment over existing conventional quantitative measures such
as tricuspid annular displacement, fractional area change,
and myocardial performance index [78, 79]. Survival, left
ventricular ejection fraction and symptoms are worse in
dilated cardiomyopathy patients with biventricular dysfunc-
tion (left ventricular ejection fraction< 50%, right ventricular
ejection fraction < 35%) compared with those with LV
dysfunction alone.
Selection of patients for a wide range of device therapies
needs also an accurate echocardiographic evaluation [80–
84]. These approaches concern cardioverter defibrillators
implantation and cardiac resynchronization therapy (CRT) in
the initial phases of dilated cardiomyopathy, while echocar-
diography may help in the decision of implantation of LV
and RV assist devices in advanced HF. The use of CRT has
been justified by prognostic benefit in HF patients with wide
QRS, but functional benefit is not uniform in these patients.
Actually, defining the response to CRT is not easy, and the
concept of nonresponsiveness is still controversial [71, 80].
3.4. Congenital Heart Disease. Adults with congenital heart
disease (CHD) have increased in number due to advances in
early diagnosis and treatment [85]. Cardiovascular imaging is
important in the long-term management of adult congenital
heart disease (ACHD) because of persistent residual or post-
operative right- and left-sided anatomic and haemodynamic
abnormalities. Since symptoms may appear late, periodic
imaging monitoring is essential to detect haemodynamic
changes [86] and assess comorbidity including acquired heart
disease that can occurwith age [87].The choice of the imaging
modality is suggested by the lesion-specific characteristics of
patients, advantages and limits of the technique, institutional
resources, and expertise of the cardiologist. A multimodality
imaging approach is often required to obtain all the necessary
structural and functional information for the management of
the postoperative patient [88–90].
Apart from the assessment of postoperative complex
CHD, nowadays echocardiography has gained an important
role in the management of patients with patent foramen
ovale (PFO) and atrial septal defect (ASD). Strokes have
high rates of morbidity being the second leading cause of
death, and up to 40% of ischaemic strokes are cryptogenic.
A strong association has been shown between cryptogenic
stroke and PFO prevalence suggesting paradoxical embolism
via PFO as a potential cause. PFO closure with Amplatzer
device appeared superior to medical therapy in preventing
strokes in patients with cryptogenic embolism [91], and
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Figure 6: A 27-year-old male patient with patent foramen ovale (PFO) and a history of transient ischaemic attack (TIA). Patient had atrial
device implantation. (a) Atrial septal aneurysm (ASA) with PFO and left-to-right shunt by transesophageal echocardiography. (b) TEE
right-to-left shunt after intravenous injection of ultrasound contrast agent. (c) Postdevice transesophageal longitudinal bicaval view showing
absence of shunt flow. LA = left atrium; RA = right atrium.
the percutaneous transcatheter closure has become a well-
established technique for the treatment of PFO and ASD up
to a diameter of 35mm [92].
PFO represents a remnant of the foetal foramen ovale
and has a flap valve mechanism that intermittently opens a
small channel between left and right atrium. It is associated
with an intermittent right-to-left shunt, only rarely with a
permanent left-to-right shunt, has an incidence of 20% to
35% of the general population, and is commonly treatable
by device closure. On the contrary, ASD is a permanent
opening characterized by left-to-right shuntingwith transient
right-to-left shunting on the basis of the breathing cycle and
accounts for nearly 10% of congenital heart disease. Different
types of ASD involve particular structures such as septum
primum (ostium primum ASD), septum secundum (ostium
secundum ASD), sinus venosus (sinus venosus ASD), and
coronary sinus (coronary sinus ASD).The ostium secundum
ASD is the most frequent type and the only one treatable by
percutaneous transcatheter closure. Indications for ASD clo-
sure are isolated secundum ASD with a pulmonary/systemic
flow (𝑄p/𝑄s) ratio ≥1.5 : 1 and signs of right ventricular
volume overload. Indications for PFO closure are cryptogenic
stroke and evidence of right to left shunt.
Transesophageal echocardiography (TEE) has become an
established approach (Figure 6) to guide the interventional
treatment of interatrial shunts [93–97]. Contrast transtho-
racic echocardiography (TTE) has a role as a screening tool in
patients with unclear right volume overload or after systemic
embolic events [98] but is not capable of differentiating
between PFO and the various kinds of ASDs and not
suitable for guiding percutaneous device closure of interatrial
communications.
Traditionally, percutaneous ASD and PFO closures are
performed under 2D-TEE guidance. TEE is also employed
prior to device closure to assess defect size, position, and any
associated left-to-right and right-to left shunting (Figure 7).
It is important to assess the ASD rims of the respective
structures: superior vena cava rim (superior), aortic rim
(anterosuperior), coronary sinus rim (anteroinferior), IVC
rim (inferior), and posterior LA rim (posterior). If the
inferior rim length is <5mm, the occluder closure is not
indicated. Absence of the aortic rim is not a contraindication
for the percutaneous closure but requires some degree of
oversizing of the device encompassing the aortic root.
Life-threatening acute congestive LV failure complicating
surgical or transcatheter closure of ASDs in patients with LV
restriction has been reported [99, 100]. Device closure is an
alternative to surgery in these patients, only on condition that
there is no right-to-left shunting, LA pressure is markedly
reduced due to echocardiography-guided preconditioning,
LA pressure remains below the critical level of 20mmHg on
the temporary ASD closure, and the interventional cardiol-
ogist is familiar with the procedure and can complete it in a
straightforward manner under echocardiographic guidance
[96].
Three-dimensional TEE (3D-TEE) offers improved spa-
tial orientation and better definition of ASD, “complex” PFO,
or multifenestrated septal aneurysm [101, 102]. The major
advantage of 3D-TEE is its capability of showing the dynamic
morphology of ASDs with complex geometries, including
elliptical, oblong, or fenestrated shapes. The technique is
also used for preinterventional assessment of the atrial lesion
and detection of complications, such as device dislodge-
ment, devicemalposition, haemorrhagic pericardial effusion,
device thrombosis, failure, or erosion.
3.5. Valvular Heart Disease. Patients with valvular heart
disease (VHD) can be asymptomatic or present with a series
of symptoms not always related to the severity of the lesion
[103]. Current guidelines [104, 105] recommend transthoracic
echocardiography (TTE) as the initial diagnostic test in
patients with known or suspected VHD. While 2D and
M-mode TTE allow assessment of valvular morphology,
Doppler provides information on haemodynamics, pressure
gradients, valve area, pulmonary artery pressure, and LV
filling [106, 107]. Transoesophageal echocardiography (TEE)
gives helpful detailed structural and hemodynamic informa-
tion. Exercise Doppler echocardiography is useful to assess
the patient’s functional capacity and the impact of exercise
on valvular and ventricular function [108–110]. Overall, the
severity of a valvular lesion is better determined on the basis
of a multiparameter echo Doppler assessment.
Mitral regurgitation (MR) is the most common clinically
recognizable valvular heart condition.Thedisease has various
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Figure 7: A 32-year-old female patient with ostium secundum atrial septal defect (ASD) and a history of ischaemic stroke. Patient had atrial
device implantation. (a) Three-dimensional apical 4-chamber view, ASD. (b) Transesophageal three-dimensional longitudinal view, ASD
shape. (c) Transesophageal 4-chamber view, left-to-right shunt by color Doppler. (d) Postdevice three-dimensional apical 4-chamber view
showing absence of shunt flow. IVC = inferior vena cava; LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle; SVC
= superior vena cava.
congenital and acquired etiologies. Mitral valve prolapse
(MVP) is a primary condition (Figure 8) characterized by a
progressive myxomatous degeneration of valve leaflets and
chordae tendineae [106, 110], differently from what occurs in
chronic ischemic mitral regurgitation which is a secondary
pathologic entity resulting from subvalvular remodeling and
leaflet tethering induced by myocardial infarction with sub-
sequent annulus dilatation and flattening. MVP represents
a slowly developing process which usually shows a benign
course, since less than 10% of valvular lesions progress to
severe regurgitation requiring surgical treatment. In some
occasions patients affected by worsening MR suffer from a
variety of symptoms mostly represented by dyspnoea and
palpitations related to secondary onset of supraventricular
tachyarrhythmias, conditions that usually require repeated
hospitalization and different diagnostic tests execution. Con-
sidering the wide diffusion of MVP, this creates high costs for
health organizations, even if only a small portion of patients
will need surgical therapy during their lifetime.
It has become evident that moderate-to-severe MR, even
in the absence of LV dilatation and dysfunction, may have
adverse prognostic consequences.Thus, accurate echocardio-
graphic quantification of MR is vitally important in clinical
medicine, especially when planning surgery or interventional
percutaneous procedures [9, 107] as the mitral clip implan-
tation (Figure 9). Because of the mitral valve’s structural
complexity, MR is often difficult to define. Both qualitative
and quantitative approaches are used. ColorDoppler imaging
allows measurement of the regurgitant jet area and vena
contracta (VC) width; these two qualitative methods are
simple to apply in daily practice but often are inaccurate,
especially in patients with eccentric MR. Two-dimensional
(2D) quantitative methods include the calculation of regur-
gitant fraction, regurgitant volume, and proximal isovelocity
surface area.With three-dimensional (3D) echocardiography,
many of the geometric assumptions necessary with 2D
imaging are obviated, such as the depiction of the VC, which
often is noncircular, and anatomic regurgitant orifice area,
which usually is nonplanar.
Aortic valve stenosis (AS) represents a significant cause of
morbidity and mortality [111]. The prevalence of calcific AS
increases with age as it is around 5% in individuals aged 55
years and around 10% in individuals aged 80 years and older.
The most common aetiology is the calcification of a normal
trileaflet valve or a congenital bicuspid valve. Rheumatic aor-
tic stenosis is less prevalent in the economically developing
regions, although it remains a frequent cause of mortality in
more economically challenged countries. The prognosis in
patients with symptomatic aortic stenosis is poor, with the
interval from the onset of symptoms to the time of death
being ∼2 years following heart failure, ∼3 years following
syncope, and ∼5 years following angina.
Complex presentations with multiple comorbid condi-
tions make often the diagnosis and management of AS
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Figure 8: A 38-year-old male patient with congenital mitral valve prolapse (MVP), mitral regurgitation (MR), and progressive dyspnea.
Patient hadmitral valve surgery. (a)MVP byM-mode echocardiography. (b) Color Doppler in apical 4-chamber view showing severeMR. (c)
Doppler-estimated systolic pulmonary artery pressure (58mmHg). (d) MR reduction after mitral valve surgery (MVmechanical prosthesis).
LA = left atrium; LV = left ventricle; MV = mitral valve; RA = right atrium; RV = right ventricle.
(a) (b) (c)
Figure 9: A 35-year-old female patient with systemic lupus erythematosus and progressive dyspnea from severe mitral regurgitation (MR).
Patient had percutaneous mitral valve (MV) clip implantation. (a) Thickened MV leaflets. (b) Severe MR by TEE. (c) MR reduction after
percutaneous MV clip implantation. Ao = aorta; LA = left atrium; LV = left ventricle.
challenging. Clinical signs and symptoms are of limited use
in distinguishing critical from noncritical AS due to unsat-
isfactory sensitivity and specificity especially in the aged.
Moreover, assessment of the symptomatic status and severity
of valvular lesion can be disappointing because of the sub-
jectivity of symptoms and ambiguity of individual functional
capacity. The current guidelines approve two-dimensional
transthoracic echocardiography (TTE) as the diagnostic test
of choice for the assessment of AS. In addition to TTE, 2D
transesophageal echocardiography (2DTEE) provides images
with higher resolution (Figure 10), while real time three-
dimensional TTE and 3DTEE facilitate spatial recognition
of both anatomy and function and allow for the direct
assessment of stenosis severity. Severe AS is conventionally
defined as a peak aortic velocity > 4m/s, a mean gradient >
40mmHg, and a valve area< 1 cm2 [111]. Indications for aortic
valve replacement are symptomatic severe AS, asymptomatic
patients with severe AS and LV ejection fraction < 50%, and
patients with severe AS undergoing cardiac surgery for other
indications.
The majority of aortic valve replacements are surgical
aortic valve replacement. However, in high-risk patient
groups, factors such as increasing age, prior cardiac surgery,
and other comorbidities, such as heart failure, respiratory,
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Figure 10: A 46-year-oldmale patient with valvar aortic stenosis (AS) and angina pectoris. Patient had aortic valve surgery. (a) Left ventricular
hypertrophy from pressure afterload. (b) High transvalvular pressure gradient (81mmHg peak, 44mmHg mean) by color Doppler. (c)
Reduced aortic valvar area (0.7 cm2) by TEE. (d) Aortic pressure gradient reduction (12mmHgpeak, 7mmHgmean) after aortic valve surgery.
Ao = aorta; IVS = interventricular septum; LA = left atrium; LV = left ventricle; PW = LV posterior wall; RA = right atrium.
and renal diseases, are associated with a high potential
for operative mortality and morbidity. Transcatheter aortic
valve implantation (TAVI) was first performed in 2002 as
a less invasive approach and is now recommended as an
alternative strategy for patients in high risk surgical groups
[112–114]. Multimodality imaging including echocardiogra-
phy, computed tomography (CT), and CMR plays a pivotal
role in the selection and planning process [113, 114]; however,
echocardiography remains the primary imaging modality for
patient selection, intraprocedural guidance, postprocedural
assessment, and long-term follow-up.
4. Conclusions
Echocardiography using both conventional and more recent
modalities is the primary diagnostic tool for the assess-
ment of early cardiac dysfunction. It is a cost-effective
technique and offers real-time imaging with high spatial
and temporal resolution. Three-dimensional echocardiog-
raphy and two-dimensional and three-dimensional speckle
tracking echocardiography may provide additional diagnos-
tic information. It is plausible that echocardiography will
further evolve in the future with improvements in technology
providing better clinical help. A strong professional liaison
between echocardiologists and occupational physicians aids
the process of offering effective support and management for
the cardiovascular patients in the workplace.
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